Phase 2 Study for High-Risk Mantle Cell Lymphoma (MCL)
This study is investigating if adding glofitamab after initial treatment with acalabrutinib or zanubrutinib (BTKi drugs) and rituximab can help control high-risk mantle cell lymphoma (MCL). MCL is a type of cancer that affects white blood cells. You may be able to join if you have a confirmed diagnosis of MCL with specific genetic markers (CD20 positivity, t(11;14) translocation, and/or cyclin D1 overexpression). Researchers will be looking at how safe the treatment is and how well it clears the cancer, specifically checking for minimal residual disease (MRD) negativity. The study aims to enroll 30 participants, but its current recruitment status is unclear.
- Study design
- This is a Phase 2 interventional study, meaning it tests a new treatment approach in a small group of people. It plans to enroll 30 participants.
- What's involved
- Not specified in the trial record.
- Compensation
- Not stated in the trial record.
- Follow-up
- Safety and adverse events will be measured through study completion, which is an average of 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesStudy leadership
- Preetesh Jain, MD · PRINCIPAL_INVESTIGATOR · M.D. Anderson Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Safety and adverse events (AEs)Through study completion; an average of 1 year
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0